Circulating CD20-positive extracellular vesicles impair rituximab efficacy and predict outcomes in diffuse large B-cell lymphoma
{{output}}
Rituximab, an anti-CD20 monoclonal antibody, is a cornerstone of therapy for diffuse large B-cell lymphoma (DLBCL), yet a substantial proportion of patients develop treatment failure. While loss of CD20 expression has been considered a major mechanism of resis... ...
